Q-Line Biotech Secures 25% Royalty Reduction in Amended Agreement with Boule Medical
Q-Line Biotech Ltd 路 Press Release 路 02 Sept 2026, 11:24 pm
Q-Line Biotech Secures 25% Royalty Reduction in Amended Agreement with Boule Medical Q-Line Biotech entered an amended license agreement with Sweden's Boule Medical AB for diagnostic reagents and haematology analyzers. A key commercial benefit is a 25% reduction in license and royalty costs payable to Boule, effective 1st Jul'26. The revised framework includes rationalized minimum purchase commitments, extended payment terms, and volume-linked benefits, enhancing Q-Line's cost efficiency in price-sensitive institutional markets. The agreement has an initial 5-year term, extendable by another 5 years, positioning the company for deeper market penetration, higher instrument placements, and increased recurring reagent volumes.
Original exchange filing (PDF)
More announcements from Q-Line Biotech Ltd
- Q-Line Biotech Limited has informed the Exchange regarding 'Submission of audio recording of Earnings Conference Call-13.11.2026'. 路 15 Nov 2026
- Q-Line Biotech Limited has informed the Exchange about Investor Presentation 路 13 Nov 2026
- Q-Line Biotech Limited has informed the Exchange about General Updates 路 13 Nov 2026
- Q-Line Biotech Limited has informed the Exchange regarding a press release dated November 12, 2026, titled "PRESS RELEASE ON FINANCIAL RESULTS 30 SEPTEMBER 2026.". 路 13 Nov 2026
- Q-Line Biotech Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 13 Nov 2026
- Q-Line Biotech Limited has informed the Exchange regarding 'Board comments on fine levied by the Exchange'. 路 13 Nov 2026
- Q-Line Biotech Limited has informed the Exchange about Schedule of meet 路 13 Nov 2026
- Q-Line Biotech Limited has informed the Exchange about Board Meeting to be held on 12-Nov-2026 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2026 and Other business. 路 12 Nov 2026
